Crispr Therapeutics (NASDAQ:CRSP) had its price target upped by investment analysts at Goldman Sachs Group from $52.00 to $75.00 in a research report issued to clients and investors on Tuesday, November 19th, The Fly reports. The firm currently has a “neutral” rating on the stock. Goldman Sachs Group’s price objective indicates a potential upside of 3.63% from the company’s previous close.
A number of other analysts have also recently weighed in on the stock. Roth Capital upped their price target on shares of Crispr Therapeutics from $50.00 to $65.00 in a research report on Tuesday, July 30th. Barclays boosted their price target on Crispr Therapeutics from $59.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. William Blair restated a “hold” rating on shares of Crispr Therapeutics in a report on Tuesday, July 30th. Canaccord Genuity began coverage on shares of Crispr Therapeutics in a research note on Friday, July 26th. They set a “buy” rating and a $72.00 price objective on the stock. Finally, ValuEngine upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $69.54.
Shares of NASDAQ CRSP opened at $72.37 on Tuesday. The stock has a market capitalization of $4.00 billion, a PE ratio of -21.04 and a beta of 3.30. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a fifty day moving average of $54.81 and a 200-day moving average of $47.38.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The firm had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Equities research analysts expect that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total transaction of $465,000.00. Following the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $465,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock worth $3,620,760 over the last quarter. 21.40% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. BSW Wealth Partners bought a new position in shares of Crispr Therapeutics during the second quarter valued at approximately $39,000. Balyasny Asset Management LLC acquired a new position in shares of Crispr Therapeutics during the second quarter valued at $5,165,000. BNP Paribas Arbitrage SA bought a new position in shares of Crispr Therapeutics during the second quarter worth about $41,000. Bank of New York Mellon Corp grew its position in shares of Crispr Therapeutics by 116.5% during the second quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock worth $1,559,000 after acquiring an additional 17,810 shares during the last quarter. Finally, ARK Investment Management LLC increased its stake in shares of Crispr Therapeutics by 34.7% in the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after purchasing an additional 701,332 shares during the period. 49.81% of the stock is currently owned by hedge funds and other institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Why are percentage decliners important?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.